The Pharma Letter19h
Beijing’s Allink secures $42 million in series A
Allink Biotherapeutics, a Chinese startup specializing in bispecific antibodies and antibody-drug conjugates, raises $42 ...
The Pharma Letter19h
More positive data for Shanghai’s Minghui
Minghui Pharmaceutical announces successful Phase III trial of MH004 for atopic dermatitis, achieving significant skin ...
The Pharma Letter19h
Enhertu added to China's health insurance plan
AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...
The Pharma Letter19h
Innovent updates on Sintbilo in China
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo ...
The Pharma Letter19h
Denmark to permanently legalize medical cannabis
The Danish Ministry of Interior and Health has announced that the political parties have decided to permanently legalize ...
The Pharma Letter23h
Final reminder on UK labelling change
Industry is showing a very high level of readiness for upcoming new packaging and labelling measures impacting the UK market, according to the Medicines and Healthcare products Regulatory Agency (MHRA ...
The Pharma Letter23h
Formosa inks deal with Medvisis for clobetasol rights
Taiwan-based Formosa Pharmaceuticals (6838: TW) revealed that it has entered into an exclusive licensing agreement with Medvisis Switzerland, in Switzerland and Liechtenstein, for exclusive rights to ...